1252 related articles for article (PubMed ID: 33972366)
21. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
[TBL] [Abstract][Full Text] [Related]
22. Re
Karges J; Kalaj M; Gembicky M; Cohen SM
Angew Chem Int Ed Engl; 2021 May; 60(19):10716-10723. PubMed ID: 33606889
[TBL] [Abstract][Full Text] [Related]
23. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
24. Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion.
Fuzo CA; Martins RB; Fraga-Silva TFC; Amstalden MK; Canassa De Leo T; Souza JP; Lima TM; Faccioli LH; Okamoto DN; Juliano MA; França SC; Juliano L; Bonato VLD; Arruda E; Dias-Baruffi M
Drug Dev Res; 2022 Nov; 83(7):1623-1640. PubMed ID: 35989498
[TBL] [Abstract][Full Text] [Related]
25. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
26. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
Viruses; 2022 May; 14(5):. PubMed ID: 35632703
[TBL] [Abstract][Full Text] [Related]
27. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
[TBL] [Abstract][Full Text] [Related]
28. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
29. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
[No Abstract] [Full Text] [Related]
30. Advances Toward COVID-19 Therapies Special Issue.
Neamati N
J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859
[No Abstract] [Full Text] [Related]
31. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
32. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
Molecules; 2021 May; 26(9):. PubMed ID: 34062737
[TBL] [Abstract][Full Text] [Related]
33. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.
Gentile D; Patamia V; Scala A; Sciortino MT; Piperno A; Rescifina A
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32340389
[TBL] [Abstract][Full Text] [Related]
34. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2.
Chen Y; Yang WH; Chen HF; Huang LM; Gao JY; Lin CW; Wang YC; Yang CS; Liu YL; Hou MH; Tsai CL; Chou YZ; Huang BY; Hung CF; Hung YL; Wang WJ; Su WC; Kumar V; Wu YC; Chao SW; Chang CS; Chen JS; Chiang YP; Cho DY; Jeng LB; Tsai CH; Hung MC
J Biol Chem; 2022 Mar; 298(3):101658. PubMed ID: 35101449
[TBL] [Abstract][Full Text] [Related]
35.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
36. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Unoh Y; Uehara S; Nakahara K; Nobori H; Yamatsu Y; Yamamoto S; Maruyama Y; Taoda Y; Kasamatsu K; Suto T; Kouki K; Nakahashi A; Kawashima S; Sanaki T; Toba S; Uemura K; Mizutare T; Ando S; Sasaki M; Orba Y; Sawa H; Sato A; Sato T; Kato T; Tachibana Y
J Med Chem; 2022 May; 65(9):6499-6512. PubMed ID: 35352927
[TBL] [Abstract][Full Text] [Related]
37. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
Vandyck K; Deval J
Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
[TBL] [Abstract][Full Text] [Related]
38. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
Marinho EM; Batista de Andrade Neto J; Silva J; Rocha da Silva C; Cavalcanti BC; Marinho ES; Nobre Júnior HV
Microb Pathog; 2020 Nov; 148():104365. PubMed ID: 32619669
[TBL] [Abstract][Full Text] [Related]
39. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
[TBL] [Abstract][Full Text] [Related]
40. Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach.
Sen D; Debnath B; Debnath P; Debnath S; Zaki MEA; Masand VH
Sci Rep; 2022 Jan; 12(1):1503. PubMed ID: 35087077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
